Table 3.
Post-diagnosis clinical events in 206 TET2-mutated or -unmutated patients with PV, ET or PMF
| PV (all patients) |
TET2 mutated |
TET2 unmutated |
ET (all patients) |
TET2 mutated |
TET2 unmutated |
PMF (all patients) |
TET2 mutated |
TET2 unmutated |
|
|---|---|---|---|---|---|---|---|---|---|
| N (%) | 89 (100) | 14 (16) | 75 (84) | 57 (100) | 3 (5) | 54 (95) | 60 (100) | 10 (17) | 50 (83) |
| Disease duration in months, median (range) | 60 (1–310) | 57 (1–191) | 60 (1–310) | 163 (0.3–398) | 89 (19–144) | 170 (0.3–398) | 48 (5–200) | 26 (6–200) | 55 (5–197) |
| Arterial thrombosis after diagnosis, n (%) | 15 (18) | 1 (7) | 14 (20) | 16 (29) | 2 (67) | 14 (27) | NA | NA | NA |
| Venous thrombosis after diagnosis, n (%) | 9 (11) | 1 (7) | 8 (11) | 7 (13) | 1 (33) | 6 (12) | NA | NA | NA |
| Leukemictransformation, n (%) | 4 (5) | 1 (7) | 3 (4) | 2 (4) | 0 | 2 (4) | 3 (5) | 1 (10) | 2 (4) |
| Fibrotic transformation, n (%) | 6 (7) | 1 (7) | 5 (7) | 3 (5) | 0 | 3 (6) | NA | NA | NA |
| Deaths, n (%) | 19 (21) | 3 (21) | 16 (21) | 13 (23) | 2 (67) | 11 (20) | 29 (48) | 7 (70) | 22 (44) |
Abbreviations: ET, essential thrombocythemia; NA, not available or not applicable; PMF, primary myelofibrosis; PV, polycythemia vera.